FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327831249> ?p ?o ?g. }

• W4327831249 endingPage "101907" @default.
• W4327831249 startingPage "101907" @default.
• W4327831249 abstract "Inhaled molecular hydrogen gas (H2) has been shown to improve outcomes in animal models of cardiac arrest (CA). H2 inhalation is safe and feasible in patients after CA. We investigated whether inhaled H2 would improve outcomes after out-of-hospital CA (OHCA).HYBRID II is a prospective, multicentre, randomised, double-blind, placebo-controlled trial performed at 15 hospitals in Japan, between February 1, 2017, and September 30, 2021. Patients aged 20-80 years with coma following cardiogenic OHCA were randomly assigned (1:1) using blinded gas cylinders to receive supplementary oxygen with 2% H2 or oxygen (control) for 18 h. The primary outcome was the proportion of patients with a 90-day Cerebral Performance Category (CPC) of 1 or 2 assessed in a full-analysis set. Secondary outcomes included the 90-day score on a modified Rankin scale (mRS) and survival. HYBRID II was registered with the University Hospital Medical Information Network (registration number: UMIN000019820) and re-registered with the Japan Registry for Clinical Trials (registration number: jRCTs031180352).The trial was terminated prematurely because of the restrictions imposed on enrolment during the COVID-19 pandemic. Between February 1, 2017, and September 30, 2021, 429 patients were screened for eligibility, of whom 73 were randomly assigned to H2 (n = 39) or control (n = 34) groups. The primary outcome, i.e., a CPC of 1 or 2 at 90 days, was achieved in 22 (56%) and 13 (39%) patients in the H2 and control groups (relative risk compared with the control group, 0.72; 95% CI, 0.46-1.13; P = 0.15), respectively. Regarding the secondary outcomes, median mRS was 1 (IQR: 0-5) and 5 (1-6) in the H2 and control groups, respectively (P = 0.01). An mRS score of 0 was achieved in 18 (46%) and 7 (21%) patients in the H2 and control groups, respectively (P = 0.03). The 90-day survival rate was 85% (33/39) and 61% (20/33) in the H2 and control groups, respectively (P = 0.02).The increase in participants with good neurological outcomes following post-OHCA H2 inhalation in a selected population of patients was not statistically significant. However, the secondary outcomes suggest that H2 inhalation may increase 90-day survival without neurological deficits.Taiyo Nippon Sanso Corporation.For the Japanese translation of the abstract see Supplementary Materials section." @default.
• W4327831249 created "2023-03-19" @default.
• W4327831249 creator A5001186569 @default.
• W4327831249 creator A5001947356 @default.
• W4327831249 creator A5003412793 @default.
• W4327831249 creator A5007109053 @default.
• W4327831249 creator A5007269253 @default.
• W4327831249 creator A5007670245 @default.
• W4327831249 creator A5008048412 @default.
• W4327831249 creator A5019044000 @default.
• W4327831249 creator A5019572813 @default.
• W4327831249 creator A5023967625 @default.
• W4327831249 creator A5024722455 @default.
• W4327831249 creator A5030600880 @default.
• W4327831249 creator A5031803033 @default.
• W4327831249 creator A5033067226 @default.
• W4327831249 creator A5035812241 @default.
• W4327831249 creator A5038009551 @default.
• W4327831249 creator A5038150368 @default.
• W4327831249 creator A5038274081 @default.
• W4327831249 creator A5045270233 @default.
• W4327831249 creator A5046089718 @default.
• W4327831249 creator A5047982024 @default.
• W4327831249 creator A5049546574 @default.
• W4327831249 creator A5050585083 @default.
• W4327831249 creator A5055556356 @default.
• W4327831249 creator A5056086679 @default.
• W4327831249 creator A5056782454 @default.
• W4327831249 creator A5069562625 @default.
• W4327831249 creator A5071489440 @default.
• W4327831249 creator A5074079456 @default.
• W4327831249 creator A5078623020 @default.
• W4327831249 creator A5078878670 @default.
• W4327831249 creator A5079036022 @default.
• W4327831249 creator A5079207845 @default.
• W4327831249 creator A5080844975 @default.
• W4327831249 creator A5081788004 @default.
• W4327831249 creator A5084132891 @default.
• W4327831249 creator A5089221103 @default.
• W4327831249 creator A5089292835 @default.
• W4327831249 creator A5091567559 @default.
• W4327831249 date "2023-04-01" @default.
• W4327831249 modified "2023-10-14" @default.
• W4327831249 title "Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care (HYBRID II): a multi-centre, randomised, double-blind, placebo-controlled trial" @default.
• W4327831249 cites W1963789809 @default.
• W4327831249 cites W1967298536 @default.
• W4327831249 cites W2053096346 @default.
• W4327831249 cites W2115944968 @default.
• W4327831249 cites W2125948531 @default.
• W4327831249 cites W2132080871 @default.
• W4327831249 cites W2137818678 @default.
• W4327831249 cites W2150197616 @default.
• W4327831249 cites W2164957370 @default.
• W4327831249 cites W2169657429 @default.
• W4327831249 cites W2171886225 @default.
• W4327831249 cites W2180469576 @default.
• W4327831249 cites W2268628191 @default.
• W4327831249 cites W2466448612 @default.
• W4327831249 cites W2472599713 @default.
• W4327831249 cites W2531429888 @default.
• W4327831249 cites W2765557965 @default.
• W4327831249 cites W2766115192 @default.
• W4327831249 cites W2801223479 @default.
• W4327831249 cites W2914264003 @default.
• W4327831249 cites W2924267611 @default.
• W4327831249 cites W2977227810 @default.
• W4327831249 cites W3035844002 @default.
• W4327831249 cites W3047098839 @default.
• W4327831249 cites W3094494803 @default.
• W4327831249 cites W3115762959 @default.
• W4327831249 cites W3171604783 @default.
• W4327831249 cites W3207190809 @default.
• W4327831249 cites W4205698737 @default.
• W4327831249 cites W4210242902 @default.
• W4327831249 cites W81660439 @default.
• W4327831249 doi "https://doi.org/10.1016/j.eclinm.2023.101907" @default.
• W4327831249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36969346" @default.
• W4327831249 hasPublicationYear "2023" @default.
• W4327831249 type Work @default.
• W4327831249 citedByCount "0" @default.
• W4327831249 crossrefType "journal-article" @default.
• W4327831249 hasAuthorship W4327831249A5001186569 @default.
• W4327831249 hasAuthorship W4327831249A5001947356 @default.
• W4327831249 hasAuthorship W4327831249A5003412793 @default.
• W4327831249 hasAuthorship W4327831249A5007109053 @default.
• W4327831249 hasAuthorship W4327831249A5007269253 @default.
• W4327831249 hasAuthorship W4327831249A5007670245 @default.
• W4327831249 hasAuthorship W4327831249A5008048412 @default.
• W4327831249 hasAuthorship W4327831249A5019044000 @default.
• W4327831249 hasAuthorship W4327831249A5019572813 @default.
• W4327831249 hasAuthorship W4327831249A5023967625 @default.
• W4327831249 hasAuthorship W4327831249A5024722455 @default.
• W4327831249 hasAuthorship W4327831249A5030600880 @default.
• W4327831249 hasAuthorship W4327831249A5031803033 @default.
• W4327831249 hasAuthorship W4327831249A5033067226 @default.
• W4327831249 hasAuthorship W4327831249A5035812241 @default.
• W4327831249 hasAuthorship W4327831249A5038009551 @default.
• W4327831249 hasAuthorship W4327831249A5038150368 @default.

• next